Corneal Collagen Cross-linking

Policy # 00325
Original Effective Date: 12/21/2011
Current Effective Date: 06/08/2020

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract.

Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Implantation of Intrastromal Corneal Ring Segments is addressed separately in medical policy 00164.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider corneal collagen cross-linking (CXL) using riboflavin and ultraviolet A (UVA) as a treatment of progressive keratoconus in patients who have failed conservative treatment (e.g., spectacle correction, rigid contact lens) to be eligible for coverage.**

Note: The correction of refractive errors of the eye, including but not limited to radial keratotomy and laser surgery, are excluded from coverage under medical benefits on majority of member contracts. In addition, treatment of complications of non-covered services are also excluded from coverage. If it is determined that corneal ectasia was a complications of refractive surgery, request for corneal collagen cross-linking will be denied as not a covered benefit.

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers corneal collagen cross-linking (CXL) using riboflavin and ultraviolet A (UVA) for all other indications to be investigational.*
Progressive keratoconus is defined as one or more of the following:

- An increase of 1 diopter (D) in the steepest keratometry value
- An increase of 1 D in regular astigmatism evaluated by subjective manifest refraction
- A myopic shift (decrease in the spherical equivalent) of 0.50 D on subjective manifest refraction
- A decrease ≥0.1 mm in the back optical zone radius in rigid contact lens wearers where other information was not available.

**Background/Overview**

**Treatment of Keratoconus and Ectasia**

The initial treatment for keratoconus often consists of hard contact lenses. A variety of keratorefractive procedures have also been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileuses, although generally, results of these techniques have been poor. Implantation of intrastromal corneal ring segments (see medical policy 00164) is an additive technique in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for penetrating keratoplasty. Penetrating keratoplasty (ie, corneal grafting) is the last line of treatment. About 20% of patients with keratoconus will require corneal transplantation. All of these treatments attempt to improve the refractive errors but are not disease-modifying.

Treatment options for ectasia include intraocular pressure-lowering drugs and intracorneal ring segments. Frequently, penetrating keratoplasty is required.

None of the currently available treatment options for keratoconus and corneal ectasia halt the progression of the disease, and corneal transplantation is the only option available when functional vision can no longer be achieved.

Corneal collagen cross-linking has the potential to slow the progression of the disease. It is performed with the photosensitizer riboflavin (vitamin B2) and ultraviolet A irradiation. There are 2 protocols for corneal collagen cross-linking:

1. Epithelium-off corneal collagen cross-linking (also known as “epi-off”): In this method, about 8 mm of the central corneal epithelium is removed under topical anesthesia to allow...
better diffusion of the photosensitizer riboflavin into the stroma. Following de-epithelialization, a solution with riboflavin is applied to the cornea (every 1-3 minutes for 30 minutes) until the stroma is completely penetrated. The cornea is then irradiated for 30 minutes with ultraviolet A 370 nm, a maximal wavelength for absorption by riboflavin, while the riboflavin continues to be applied. The interaction of riboflavin and ultraviolet A causes the formation of reactive oxygen species, leading to additional covalent bonds (cross-linking) between collagen molecules, resulting in stiffening of the cornea. Theoretically, by using a homogeneous light source and absorption by riboflavin, the structures beyond a 400-mm thick stroma (endothelium, anterior chamber, iris, lens, retina) are not exposed to an ultraviolet dose that is above the cytotoxic threshold.

2. Epithelium-on corneal collagen cross-linking (also known as “epi-on” or transepithelial): In this method, the corneal epithelial surface is left intact (or may be partially disrupted) and a longer riboflavin loading time is needed.

Currently, the only corneal collagen cross-linking treatment approved by the U.S. Food and Drug Administration (FDA) is the epithelium-off method. There are no FDA approved corneal collagen cross-linking treatments using the epithelium-on method. Corneal collagen cross-linking is being evaluated primarily for corneal stabilization in patients with progressive corneal thinning, such as keratoconus and corneal ectasia following refractive surgery. Corneal collagen cross-linking may also have anti-edematous and antimicrobial properties.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

In 2016, riboflavin 5'-phosphate in 20% dextran ophthalmic solution (Photrex Viscous®; Avedro) and riboflavin 5'-phosphate ophthalmic solution (Photrex®; Avedro) were approved by the FDA for use with KXL System in corneal corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia after refractive surgery.

**Rationale/Source**

Corneal collagen cross-linking is a photochemical procedure approved by the U.S. Food and Drug Administration (FDA) for the treatment of progressive keratoconus and corneal ectasia. Keratoconus is a dystrophy of the cornea characterized by progressive deformation (steepening) of the cornea.
Corneal Collagen Cross-linking

Policy #  00325
Original Effective Date:  12/21/2011
Current Effective Date:  06/08/2020

While corneal ectasia is keratoconus that occurs after refractive surgery. Both lead to functional loss of vision and need for corneal transplantation.

For individuals who have progressive keratoconus who receive corneal collagen cross-linking using riboflavin and ultraviolet A, the evidence includes multiple randomized controlled trials (RCTs), systematic reviews, and nonrandomized studies. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. In both pivotal RCTs, the primary endpoint (an intermediate outcome) of reducing maximum corneal curvature by 1 diopter (D) was achieved at month 3 and maintained at months 6 and 12 in corneal collagen cross-linking treated patients compared with sham controls. In both RCTs, the difference in mean change in maximum corneal curvature from baseline to 12 months was 1.9 D and 2.3 D, respectively, favoring the corneal collagen cross-linking treated patients. Several other studies measured visual acuity and found significant and lasting improvements in corrected visual acuity and other measures with corneal collagen cross-linking. Long-term follow-up for visual acuity outcomes is needed. The adverse events associated with corneal collagen cross-linking include corneal opacity (haze), corneal epithelial defects, and other ocular findings. Most adverse events resolved in the first month but continued in a few (1%-6%) patients for 6 to 12 months. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have corneal ectasia after refractive surgery who receive corneal collagen cross-linking using riboflavin and ultraviolet A, the evidence includes multiple RCTs and nonrandomized studies. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. In both pivotal RCTs, the primary endpoint (an intermediate outcome) of reducing maximum corneal curvature by 1 D was achieved at month 3 and maintained at months 6 and 12 in the corneal collagen cross-linking treated patients compared with sham controls. In both RCTs, the difference in mean change in maximum corneal curvature from baseline to 12 months was 2.0 D and 1.1 D, respectively, favoring corneal collagen cross-linking treated patients. Other trials showed significant improvements not only in maximum corneal curvature but also visual acuity measures in the corneal collagen cross-linking groups compared with the control groups. The first and longest trial followed patients up to 3 years and saw continued improvement in visual acuity with corneal collagen cross-linking. Long-term follow-up for visual acuity outcomes is needed. The adverse events associated with corneal collagen cross-linking were the same for the ectasia trials as for the keratoconus. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
Corneal Collagen Cross-linking

Policy # 00325
Original Effective Date: 12/21/2011
Current Effective Date: 06/08/2020

**Supplemental Information**

**Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 1 physician specialty society and 1 academic medical center (2 reviewers) while this policy was under review in 2012. The input was mixed, noting the limited literature and lack of U.S. Food and Drug Administration (FDA) approval for this procedure, although there are ongoing clinical trials regulated by the FDA. Reviewers also commented on the lack of alternatives to slow disease progression, and that data indicated the procedure is safe and effective enough to offer to patients with adequate informed consent under an investigational protocol.

**Practice Guidelines and Position Statements**

*National Institute for Health and Care Excellence*

In 2013, the National Institute for Health and Care Excellence (NICE) issued guidance on corneal collagen cross-linking using riboflavin and ultraviolet A, updating its 2009 guidance. The 2013 guidance stratified recommendations for corneal collagen cross-linking as follows:

“Most of the published evidence on photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A (UVA) for keratoconus and keratectasia relates to the technique known as ‘epithelium-off corneal collagen cross-linking’. ‘Epithelium-on (transepithelial) corneal collagen cross-linking’ is a more recent technique and less evidence is available on its safety and efficacy. Either procedure (epithelium-off or epithelium-on corneal collagen cross-linking) can be combined with other interventions, and the evidence base for these combination procedures (known as ‘corneal collagen cross-linking plus’) is also limited. Therefore, different recommendations apply to the variants of this procedure, as follows.

1.1 Current evidence on the safety and efficacy of epithelium-off corneal collagen cross-linking for keratoconus and keratectasia is adequate in quality and quantity. Therefore, this
Corneal Collagen Cross-linking

Policy #  00325
Original Effective Date:  12/21/2011
Current Effective Date:  06/08/2020

...procedure can be used provided that normal arrangements are in place for clinical governance, consent and audit.

1.2 Current evidence on the safety and efficacy of epithelium-on (transepithelial) corneal collagen cross-linking, and the combination (corneal collagen cross-linking plus) procedures for keratoconus and keratectasia is inadequate in quantity and quality. Therefore, these procedures should only be used with special arrangements for clinical governance, consent and audit or research.”

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01604135</td>
<td>Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial</td>
<td>200</td>
<td>May 2019</td>
</tr>
<tr>
<td>NCT01708538a</td>
<td>Phase III Study of Corneal Collagen Cross-linking Using Two Different Techniques</td>
<td>30</td>
<td>Oct 2020</td>
</tr>
<tr>
<td>NCT03531047</td>
<td>A Prospective, Controlled Study of Refractive Corneal Cross-linking for Progressive Keratoconus</td>
<td>52</td>
<td>Nov 2021</td>
</tr>
<tr>
<td>NCT01112072</td>
<td>Randomized Study of Safety and Efficacy of Corneal Collagen</td>
<td>160</td>
<td>Dec 2021</td>
</tr>
</tbody>
</table>
# Corneal Collagen Cross-linking

**Policy #** 00325  
**Original Effective Date:** 12/21/2011  
**Current Effective Date:** 06/08/2020

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03319082(^a)</td>
<td>A Phase IV Observational Registry to Assess the Durability of Effect of Corneal Collagen Cross-linking With Photrexa Viscous, Photrexa, and the KXL System in Patients With Corneal Ectasia Following Refractive Surgery</td>
<td>200</td>
<td>Jul 2023</td>
</tr>
<tr>
<td>NCT03760432</td>
<td>Clinical Trial of Laser Custom Corneal Collagen Cross-Linking in Keratoconus</td>
<td>100</td>
<td>Dec 2023</td>
</tr>
<tr>
<td>NCT00560651</td>
<td>German Corneal Cross-Linking Registry</td>
<td>7500</td>
<td>Nov 2027</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01459679(^a)</td>
<td>A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery</td>
<td>4000</td>
<td>Jan 2016 (terminated; updated 07/05/18)</td>
</tr>
<tr>
<td>NCT01344187(^a)</td>
<td>A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus</td>
<td>236</td>
<td>Jun 2016 (updated 06/13/18)</td>
</tr>
</tbody>
</table>
Corneal Collagen Cross-linking

Policy # 00325
Original Effective Date: 12/21/2011
Current Effective Date: 06/08/2020

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01972854a</td>
<td>A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus</td>
<td>92</td>
<td>Apr 2017 (terminated; updated 06/13/18)</td>
</tr>
<tr>
<td>NCT01189864a</td>
<td>Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas</td>
<td>500</td>
<td>Dec 2018 (terminated; updated 10/12/18)b</td>
</tr>
<tr>
<td>NCT02721628</td>
<td>Femtosecond Laser Assisted Epi-keratoplasty Versus Collagen Cross-Linking in Progressive Keratoconus</td>
<td>60</td>
<td>Mar 2018 (unknown; updated 03/29/16)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
a Denotes industry-sponsored or cosponsored trial.
b Terminated to initiate FDA and IND-cleared study protocol.

References
6. U.S. Food and Drug Administration. FDA Briefing Package for Joint Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Device Panel of the

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Corneal Collagen Cross-linking

Policy # 00325
Original Effective Date: 12/21/2011
Current Effective Date: 06/08/2020


©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Corneal Collagen Cross-linking

Policy # 00325
Original Effective Date: 12/21/2011
Current Effective Date: 06/08/2020


Policy History
Original Effective Date: 12/21/2011
Current Effective Date: 06/08/2020

12/08/2011 Medical Policy Committee review
12/06/2012 Medical Policy Committee review
12/19/2012 Medical Policy Implementation Committee approval. No change to coverage.
11/07/2013 Medical Policy Committee review
11/06/2014 Medical Policy Committee review
Corneal Collagen Cross-linking

Policy # 00325
Original Effective Date: 12/21/2011
Current Effective Date: 06/08/2020

08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
10/29/2015 Medical Policy Committee review
11/16/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/03/2016 Medical Policy Committee review
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
11/02/2017 Medical Policy Committee review

11/08/2018 Medical Policy Committee review
01/01/2019 Coding update
11/07/2019 Medical Policy Committee review
11/13/2019 Medical Policy Implementation Committee approval. Coverage changes “or corneal ectasia after refractive surgery” removed from coverage statement and note added for clarity stating “The correction of refractive errors of the eye, including but not limited to radial keratotomy and laser surgery, are excluded from coverage under medical benefits on majority of member contracts. In addition, treatment of complications of non-covered services are also excluded from coverage. If it is determined that corneal ectasia was a complications of refractive surgery, request for corneal collagen cross-linking will be denied as not a covered benefit.”
05/07/2020 Medical Policy Committee review
05/13/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 05/2021
Corneal Collagen Cross-linking

Policy # 00325
Original Effective Date: 12/21/2011
Current Effective Date: 06/08/2020

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2019 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>0402T, 66999</td>
</tr>
<tr>
<td>HCPCS</td>
<td>J2787</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or

3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;

B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.
Corneal Collagen Cross-linking

Policy #  00325  
Original Effective Date:  12/21/2011  
Current Effective Date:  06/08/2020

**NOTICE:**  If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:**  Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.